Clinical Trials Logo

Severe Preeclampsia clinical trials

View clinical trials related to Severe Preeclampsia.

Filter by:

NCT ID: NCT01538121 Not yet recruiting - Clinical trials for Antiphospholipid Syndrome

Antiphospholipid Antibodies and Early Severe Preeclampsia.

Start date: June 2015
Phase: N/A
Study type: Observational

The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and obstetric complications (miscarriages, stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis includes the development of severe preeclampsia before 34 weeks of gestation, but this was done without solid evidence of a relation between the two. Our study will try to add information to this particular point.

NCT ID: NCT01408979 Completed - Severe Preeclampsia Clinical Trials

Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia

MgSO4
Start date: August 2011
Phase: Phase 4
Study type: Interventional

Magnesium sulfate is the ideal drug for seizures prophilaxis in preeclampsia. The ideal duration of this treatment after delivery is still to be established. The hypothesis is that in stable patients a shorter course of treatment is possible without prejudice to the mother.

NCT ID: NCT01382732 Recruiting - Clinical trials for Postpartum Hemorrhage

Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia

Start date: January 2012
Phase: Phase 3
Study type: Interventional

Postpartum hemorrhage is an important cause of maternal morbidity and mortality. In patients with severe preeclampsia there is an increased risk of postpartum hemorrhage but the hemodynamic changes associated with this pathology make the management of any kind of bleeding particularly troublesome. There are many pharmacological options, being oxytocin the first line of treatment. However there is no evidence about the safety and efficacy of carbetocin, an oxytocin agonist. The investigators aimed to compare oxytocin with carbetocin for the routine prevention of postpartum hemorrhage in patients with severe preeclampsia.